📊 HLYK Key Takeaways
Is HealthLynked Corp (HLYK) a Good Investment?
HealthLynked faces imminent financial distress with negative stockholders' equity of -$5.8M, only $37.1K cash reserves, and operating cash burn of -$1.7M annually. Revenue collapsed 31.3% YoY while the company burns cash at a rate that depletes remaining liquidity in approximately 3 weeks, creating acute solvency risk.
Revenue is contracting sharply while losses and negative free cash flow persist, leaving the company with severe liquidity stress and negative equity. Despite an asset-light model with very high gross margins and some YoY loss improvement, the cash position and working capital deficits imply a high probability of dilutive financing or restructuring absent a rapid turnaround.
Why Buy HealthLynked Corp Stock? HLYK Key Strengths
- Exceptional gross margin of 90.7% demonstrates viable core unit economics in medical services delivery
- Net loss improved 46.5% YoY suggesting operational cost controls are taking effect
- Healthcare services sector has structural demand tailwinds if company survives liquidity crisis
- Very high gross margin (~91%) indicating an asset-light, scalable model
- YoY improvement in net loss/EPS despite downturn
- Minimal capex needs supporting potential operating leverage if growth returns
HLYK Stock Risks: HealthLynked Corp Investment Risks
- Negative equity of -$5.8M means liabilities exceed all assets - company is technically insolvent
- Critical liquidity crisis: $37.1K cash against $7.5M liabilities with monthly burn rate exceeding available cash
- Severe revenue decline of 31.3% YoY with no evidence of stabilization or recovery trajectory
- Negative operating cash flow of -$1.7M and free cash flow margin of -83.1% indicate unsustainable operations
- Current ratio of 0.22x shows inability to service short-term obligations from current assets
- Acute liquidity risk: cash ~$37k, current ratio 0.22x, negative equity
- Sustained operating losses and deeply negative FCF with poor interest coverage
- Revenue down 31% YoY, signaling demand and execution challenges
Key Metrics to Watch
- Monthly cash burn rate and estimated runway to insolvency/capital injection deadline
- Revenue trend reversal: Whether next quarter stabilizes the -31% YoY decline
- Operating cash flow return to positive: Critical survival metric given current burn
- Capital raise or debt restructuring announcements to address negative equity
- Customer acquisition cost versus lifetime value trends in medical services segment
- Operating cash flow and cash runway (cash balance/current ratio)
- Revenue growth (YoY and sequential) with gross margin stability
HealthLynked Corp (HLYK) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
HLYK Profit Margin, ROE & Profitability Analysis
HLYK vs Services Sector: How HealthLynked Corp Compares
How HealthLynked Corp compares to Services sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is HealthLynked Corp Stock Overvalued? HLYK Valuation Analysis 2026
Based on fundamental analysis, HealthLynked Corp has mixed fundamental signals relative to the Services sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
HealthLynked Corp Balance Sheet: HLYK Debt, Cash & Liquidity
HLYK Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: HealthLynked Corp's revenue has declined by 25% over the 5-year period, indicating business contraction. The most recent EPS of $-2.18 indicates the company is currently unprofitable.
HLYK Revenue Growth, EPS Growth & YoY Performance
HLYK Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $388.5K | -$701.0K | $-0.30 |
| Q2 2025 | $592.4K | -$701.0K | $0.00 |
| Q1 2025 | $774.2K | -$1.1M | $0.00 |
| Q2 2023 | $35.5K | $448.5K | $0.00 |
| Q1 2023 | $16.3K | -$1.2M | N/A |
| Q3 2022 | $1.3M | -$368.0K | $0.00 |
| Q2 2022 | $1.4M | -$505.8K | $0.00 |
| Q1 2022 | $1.4M | -$1.2M | $-0.01 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
HealthLynked Corp Dividends, Buybacks & Capital Allocation
HLYK SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for HealthLynked Corp (CIK: 0001680139)
📋 Recent SEC Filings
❓ Frequently Asked Questions about HLYK
What is the AI rating for HLYK?
HealthLynked Corp (HLYK) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 91% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are HLYK's key strengths?
Claude: Exceptional gross margin of 90.7% demonstrates viable core unit economics in medical services delivery. Net loss improved 46.5% YoY suggesting operational cost controls are taking effect. ChatGPT: Very high gross margin (~91%) indicating an asset-light, scalable model. YoY improvement in net loss/EPS despite downturn.
What are the risks of investing in HLYK?
Claude: Negative equity of -$5.8M means liabilities exceed all assets - company is technically insolvent. Critical liquidity crisis: $37.1K cash against $7.5M liabilities with monthly burn rate exceeding available cash. ChatGPT: Acute liquidity risk: cash ~$37k, current ratio 0.22x, negative equity. Sustained operating losses and deeply negative FCF with poor interest coverage.
What is HLYK's revenue and growth?
HealthLynked Corp reported revenue of $2.1M.
Does HLYK pay dividends?
HealthLynked Corp pays dividends, with $2.3M distributed to shareholders in the trailing twelve months.
Where can I find HLYK SEC filings?
Official SEC filings for HealthLynked Corp (CIK: 0001680139) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is HLYK's EPS?
HealthLynked Corp has a diluted EPS of $-1.16.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is HLYK a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, HealthLynked Corp has a STRONG SELL rating with 91% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is HLYK stock overvalued or undervalued?
Valuation metrics for HLYK: ROE of N/A (sector avg: 16%), net margin of -158.8% (sector avg: 10%). Compare these metrics with sector averages to assess valuation.
Should I buy HLYK stock in 2026?
Our dual AI analysis gives HealthLynked Corp a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is HLYK's free cash flow?
HealthLynked Corp's operating cash flow is $-1.7M, with capital expenditures of $2.6K. FCF margin is -83.1%.
How does HLYK compare to other Services stocks?
Vs Services sector averages: Net margin -158.8% (avg: 10%), ROE N/A (avg: 16%), current ratio 0.22 (avg: 1.5).